Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kymera Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$396.78M. For fiscal 2025 it was -$341.09M. The highest annual figure on record is -$41.38M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$341.09M | – |
| FY2024 | Dec 31, 2024 | -$254.26M | – |
| FY2023 | Dec 31, 2023 | -$161.97M | – |
| FY2022 | Dec 31, 2022 | -$158.28M | – |
| FY2021 | Dec 31, 2021 | -$98.13M | – |
| FY2020 | Dec 31, 2020 | -$44.54M | – |
| FY2019 | Dec 31, 2019 | -$41.38M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$145.21M | – |
| Q2 FY2026 | Jun 30, 2026 | -$73.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$82.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$95.86M | – |
| Q3 FY2025 | Sep 30, 2025 | -$90.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$82.47M | – |
| Q1 FY2025 | Mar 31, 2025 | -$72.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$78.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$70.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$48.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$56.37M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$56.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$44.45M | – |
| Q4 FY2022 | Dec 31, 2022 | -$37.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$44.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$40.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$36.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$27.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.42M | – |
See a number that looks wrong?